- Home
- BCAL vs PRTA Comparison
BCAL vs PRTA Comparison
Compare BCAL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAL
- PRTA
- Stock Information
- Founded
- BCAL 2001
- PRTA 2012
- Country
- BCAL United States
- PRTA Ireland
- Employees
- BCAL N/A
- PRTA N/A
- Industry
- BCAL Major Banks
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- BCAL Finance
- PRTA Health Care
- Exchange
- BCAL Nasdaq
- PRTA Nasdaq
- Market Cap
- BCAL 528.7M
- PRTA 472.1M
- IPO Year
- BCAL N/A
- PRTA N/A
- Fundamental
- Price
- BCAL $17.29
- PRTA $9.90
- Analyst Decision
- BCAL Buy
- PRTA Buy
- Analyst Count
- BCAL 2
- PRTA 9
- Target Price
- BCAL $19.50
- PRTA $13.14
- AVG Volume (30 Days)
- BCAL 110.4K
- PRTA 686.4K
- Earning Date
- BCAL 10-24-2025
- PRTA 11-11-2025
- Dividend Yield
- BCAL N/A
- PRTA N/A
- EPS Growth
- BCAL 15.70
- PRTA N/A
- EPS
- BCAL 0.99
- PRTA N/A
- Revenue
- BCAL $157,669,000.00
- PRTA $10,341,000.00
- Revenue This Year
- BCAL $71.01
- PRTA N/A
- Revenue Next Year
- BCAL $2.69
- PRTA $602.32
- P/E Ratio
- BCAL $17.44
- PRTA N/A
- Revenue Growth
- BCAL 80.55
- PRTA N/A
- 52 Week Low
- BCAL $11.87
- PRTA $4.32
- 52 Week High
- BCAL $18.49
- PRTA $18.88
- Technical
- Relative Strength Index (RSI)
- BCAL 57.13
- PRTA 53.43
- Support Level
- BCAL $16.61
- PRTA $9.61
- Resistance Level
- BCAL $17.55
- PRTA $10.61
- Average True Range (ATR)
- BCAL 0.54
- PRTA 0.46
- MACD
- BCAL 0.01
- PRTA -0.12
- Stochastic Oscillator
- BCAL 77.98
- PRTA 20.93
About BCAL Southern California Bancorp
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.